Brief: Atossa Therapeutics Receives FDA "Study May Proceed" Letter For (Z)-Endoxifen
06/01/2026 14:12
Jan 6 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS RECEIVES FDA "STUDY MAY PROCEED" LETTER FOR (Z)-ENDOXIFEN INVESTIGATIONAL NEW DRUG APPLICATION FOR METASTATIC BREAST CANCER Source text: ID:nPn9rvQyxa Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary